Drugs.com - New Drug Approvals

Enhertu Approved as First HER2-Directed Therapy for Patients with HER2-Low or HER2-Ultralow Metastatic Breast Cancer

27 January 2025 -- AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been approved in the US for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-low (IHC 1+ or IHC...

Feb 9, 2025 - 22:25
 0
Enhertu Approved as First HER2-Directed Therapy for Patients with HER2-Low or HER2-Ultralow Metastatic Breast Cancer
27 January 2025 -- AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been approved in the US for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-low (IHC 1+ or IHC...
Read More

Tags:

Previous Article

FDA Approves Ozempic (semaglutide) as the Only GLP-1 RA to Reduce the Risk of Wo...

Next Article

FDA Approves Leqembi (lecanemab-irmb) IV Maintenance Dosing for the Treatment of...

Related Posts

Vertex Announces U.S. FDA Approval for Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Include Additional Non-F508del Trikafta-Responsive Variants

Vertex Announces U.S. FDA Approval for Trikafta (elexac...

Feb 9, 2025  0

FDA Approves Emblaveo (aztreonam and avibactam) for the Treatment of Adults With Complicated Intra-Abdominal Infections

FDA Approves Emblaveo (aztreonam and avibactam) for the...

Feb 10, 2025  0

FDA Approves Vimkunya (chikungunya vaccine, recombinant) for Prevention of Disease Caused by Chikungunya Virus

FDA Approves Vimkunya (chikungunya vaccine, recombinant...

Feb 17, 2025  0